Company Overview and News
Biotechnology companies offer big risk, but big reward as well. These are seen as some of the more speculative companies in the market because a single clinical trial could either be a huge sunk cost or the next blockbuster drug.
NBIX IBB CLVS
2018-09-10 247wallst - 2
Stocks were indicated to open higher on Monday after a choppy prior week. Investors have seen less upside when they have bought the market pullbacks than in prior years, and investors need to be considering how they want their investments positioned for the rest of 2018.
WFCNP ATHTF STZ.B NKE AMZN AEP MS AKAM GWP OSTK WFC NBIX STZ ANTM HL TRI FL UNH ANTX
2018-09-05 seekingalpha - 8
While much attention is being riveted on the S&P 500's new all-time high eclipsing the January one, small caps accomplished that in May.
VRTX ECYT VSTM TRXC VKTX ENL CVS LGNDZ RGNX IMMU BIIB LGNYZ REGI HRTX NVTA NBIX ARWR SRPT ICPT VKTXW XLRN FNKO MRTX LGNZZ LGND NVS HEAR LGNXZ NTRA UNH PFE ENDP
2018-08-31 investorplace - 5
As we head into the later months of 2018, here are some of the best smart money stocks to buy that will finish out 2018 in style.
WFCNP DB TEVA TEVVF NFLX ADBE ALXN AMAT HRTX CBS WFC CBS.A NBIX CBS.WD BABA EXPE TEVJF MU CPV UNH
2018-08-30 investorplace - 2
Although stocks have experienced a rough start so far in 2018, some stocks still have a big chance to shine this year. The best stocks to buy now go above and beyond the normal growth prospects. While looking for these kinds of investments, I examined seven of the best stocks to invest in, all with huge upside potential and support from the Street’s top analysts.
CBS ARNA CLDR CBS.A NBIX PLAY CPV CBS.WD SBGI LAUR
This week, while Allergan’s (AGN - Free Report) uterine fibroids candidate was rejected by the FDA on safety concerns, Merck (MRK - Free Report) and Bristol-Myers’ (BMY - Free Report) PD-L1 inhibitors, Keytruda and Opdivo, respectively were approved for label expansions by the agency. AstraZeneca’s (AZN - Free Report) lung cancer drug Tagrisso gained approval in Japan in the first-line setting. Novo Nordisk (NVO - Free Report) bought a small U.
MRK NWL AZN AGN AZN NBIX PFE
AbbVie Inc. (ABBV - Free Report) and its partner Neurocrine Biosciences announced positive top-line data from phase III ELARIS UF-EXTEND extension study on Elagolix for the treatment of uterine fibroids in women. Outcomes from the phase III ELARIS UF-EXTEND (M12-816) trial demonstrated that Elagolix (300 mg twice daily) in combination with low-dose add-back therapy, reduced heavy menstrual bleeding in 87.
AGN GILD NBIX ABBV ILMN ABBV
2018-08-08 247wallst - 1
Increasingly, the Wall Street firms we cover are starting to agree that while the U.S. economy’s future is very bright, that future may be one of stock market gains much lower than the norm has been over the past 10 years. When that is the case, then investing strategies often shift from indexing to a more disciplined stock-picking routine. That’s when investors need solid growth ideas.
TTWO NBIX ATVI EXAS
Stocks were indicated to higher on Tuesday after Monday’s recovery rally. Investors have seen a very strong earnings season, with 80% of the S&P 500 reporting earnings and over 70% exceeding expectations. That said, the volatility in 2018 has created a less rewarding “buy every dip” than had been seen in prior years. Many investors are also trying to decide how they want their investments positioned ahead of the midterm elections and with international trade concerns.
Z OBSV ILMN SEAS ALXN AMAT AVGO WMB MS ETSY ABX CBS ALKS ABX WYNN PDCE CBS.A PHM NBIX CBS.WD ACAD ZG TRI CPV BRCM ALDR ALNY
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to NBIX / Neurocrine Biosciences, Inc. on message board site Silicon Investor.
|Neurocrine Biosciences (NBIX)||Neurocrine Biosciences (NBIX)||Neurocrine Biosciences (NBIX)|
as of ET